Recommended Topic Related To:

Mepron

"A family of bacteria has become increasingly resistant to last-resort antibiotics during the past decade, and more hospitalized patients are getting lethal infections that, in some cases, are impossible to cure. The findings, published today"...

Mepron

Mepron Side Effects Center

Medical Editor: Charles Patrick Davis, MD, PhD

Mepron (atovaquone), an antiprotozoal agent, is indicated for the prevention of Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX) and is indicated for the acute oral treatment of mild-to-moderate PCP in patients who are intolerant to TMP-SMX. Some serious side effects include but are not limited to: easy bruising or bleeding, unusual weakness, fever, or flu symptoms.

MEPRON (atovaquone) is supplied in strength of 750 mg atovaquone in each teaspoonful (5 mL). Dosing varies for adults and pediatric patients and is determined by the prescribing doctor. Note that failure to administer Mepron Suspension with meals may limit response to therapy. Those allergic to atovaquone should not use this medication. Mepron may interact with other medications such as rifabutin, rifampin, blood thinners, or seizure medications. There are no adequate studies on pregnant women using Mepron. Mepron should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is unknown whether Mepron is excreted into human milk. Caution is advised when administering this drug to nursing women.

Our Mepron (atovaquone) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Mepron in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

  • easy bruising or bleeding, unusual weakness;
  • fever, flu symptoms;
  • white patches in your mouth or throat;
  • worsening cough;
  • bronchospasm (wheezing, chest tightness, trouble breathing);
  • fever, sore throat, and headache with a severe blistering, peeling, and red skin rash; or
  • nausea, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Less serious side effects may include:

  • mild nausea, vomiting, stomach pain or upset,
  • diarrhea, constipation;
  • headache;
  • weakness, dizziness;
  • muscle pain;
  • mild skin rash;
  • sweating; or
  • sleep problems (insomnia).

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Mepron (Atovaquone) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Mepron Overview - Patient Information: Side Effects

SIDE EFFECTS: Stomach upset/pain, nausea, vomiting, diarrhea, constipation, loss of appetite, headache, dizziness, trouble sleeping, fever, sweating, or a strange taste in the mouth may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur: mental/mood changes (e.g., depression, anxiety), unusual weakness.

Tell your doctor immediately if any of these rare but very serious side effects occur: vision changes, change in the amount of urine, unusual bleeding/bruising, dark urine, yellowing eyes/skin, severe stomach/abdominal pain, persistent nausea/vomiting.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any of the following symptoms of a serious allergic reaction: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

Atovaquone can commonly cause a mild rash that is usually not serious. However, you may not be able to tell it apart from a rare rash that could be a sign of a severe allergic reaction. Therefore, seek immediate medical attention if you develop any rash.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Mepron (Atovaquone)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Mepron FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Because many patients who participated in clinical trials with MEPRON had complications of advanced HIV disease, it was often difficult to distinguish adverse events caused by MEPRON from those caused by underlying medical conditions. There were no life-threatening or fatal adverse experiences caused by MEPRON.

PCP Prevention Studies

In the dapsone comparative study of MEPRON Suspension, adverse experience data were collected only for treatment-limiting events. Among the entire population (n = 1,057), treatment-limiting events occurred at similar frequencies in patients treated with MEPRON Suspension or dapsone (Table 6). Among patients who were taking neither dapsone nor atovaquone at enrollment (n = 487), treatment-limiting events occurred in 43% of patients treated with dapsone and 20% of patients treated with MEPRON Suspension (P < 0.001). In both populations, the type of treatment-limiting events differed between the 2 treatment arms. Hypersensitivity reactions (rash, fever, allergic reaction) and anemia were more common in patients treated with dapsone, while gastrointestinal events (nausea, diarrhea, and vomiting) were more common in patients treated with MEPRON Suspension.

Table 6: Treatment-Limiting Adverse Experiences in the Dapsone Comparative PCP Prevention Study

Treatment-Limiting Adverse Experience Percentage of Patients with Treatment-Limiting Adverse Experience
All Patients Patients Not Taking Either Drug at Enrollment
MEPRON 1,500 mg/day
(n = 536)
Dapsone 100 mg/day
(n = 521)
MEPRON 1,500 mg/day
(n = 238)
Dapsone 100 mg/day
(n = 249)
Any event 24.4 25.9 20.2 43.4
Rash 6.3 8.8 7.6 16.1
Nausea 4.1 0.6 2.5 0.8
Diarrhea 3.2 0.2 2.1 0.4
Vomiting 2.2 0.6 1.3 0.8
Allergic reaction 1.1 2.9 0.8 4.8
Fever 0.6 2.9 0 5.6
Anemia 0 1.5 0 2

Table 7 summarizes the clinical adverse experiences reported by ≥ 20% of patients in any group in the aerosolized pentamidine comparative study of MEPRON Suspension (n = 549), regardless of attribution. The incidence of adverse experiences at the recommended dose was similar to that seen with aerosolized pentamidine. Rash was the only individual adverse experience that occurred significantly more commonly in patients treated with both dosages of MEPRON Suspension (39% to 46%) than in patients treated with aerosolized pentamidine (28%). Among patients treated with MEPRON Suspension, there was no evidence of a dose-related increase in the incidence of adverse experiences. Treatment-limiting adverse experiences occurred less often in patients treated with aerosolized pentamidine (7%) than in patients treated with 1,500 mg MEPRON Suspension once daily (25%, P ≤ 0.001) or 750 mg MEPRON Suspension once daily (16%, P = 0.004). The most common adverse experiences requiring discontinuation of dosing in the group receiving 1,500 mg MEPRON Suspension once daily were rash (6%), diarrhea (4%), and nausea (3%). The most common adverse experience requiring discontinuation of dosing in the group receiving aerosolized pentamidine was bronchospasm (2%).

Table 7: Treatment-Emergent Adverse Experiences in the Aerosolized Pentamidine Comparative PCP Prevention Study

Treatment-Emergent Adverse Experience Percentage of Patients with Treatment-Emergent Adverse Experience
MEPRON 1,500 mg/day
(n = 175)
MEPRON 750 mg/day
(n = 188)
Aerosolized Pentamidine
(n = 186)
Diarrhea 42 42 35
Rash 39 46 28
Headache 28 31 22
Nausea 26 32 23
Cough increased 25 25 31
Fever 25 31 18
Rhinitis 24 18 17
Asthenia 22 31 31
Infection 22 18 19
Abdominal pain 20 21 20
Dyspnea 15 21 16
Vomiting 15 22 11
Patients discontinuing therapy due to an adverse experience 25 16 7
Patients reporting at least 1 adverse experience 98 96 89

Other events occurring in ≥ 10% of the patients receiving the recommended dose of MEPRON included sweating, flu syndrome, pain, sinusitis, pruritus, insomnia, depression, and myalgia. Bronchospasm occurred more frequently in patients receiving aerosolized pentamidine (11%) than in patients receiving MEPRON 1,500 mg/day (4%) and MEPRON 750 mg/day (2%).

Neither MEPRON nor aerosolized pentamidine was associated with a substantial change from baseline values in any measured laboratory parameter, nor were there any significant differences in any measured laboratory parameter between MEPRON and aerosolized pentamidine. Some patients had laboratory abnormalities considered serious by the investigator or that contributed to discontinuation of therapy.

PCP Treatment Studies

Table 8 summarizes all the clinical adverse experiences reported by ≥ 5% of the study population during the TMP-SMX comparative study of MEPRON (n = 408), regardless of attribution. The incidence of adverse experiences with MEPRON Suspension at the recommended dose was similar to that seen with the tablet formulation of atovaquone.

Table 8: Treatment-Emergent Adverse Experiences in the TMP-SMX Comparative PCP Treatment Study

Treatment-Emergent Adverse Experience Percentage of Patients with Treatment-Emergent Adverse Experience
MEPRON
(n = 203)
TMP-SMX
(n = 205)
Rash (including maculopapular) 23 34
Nausea 21 44
Diarrhea 19 7
Headache 16 22
Vomiting 14 35
Fever 14 25
Insomnia 10 9
Asthenia 8 8
Pruritus 5 9
Monilia, oral 5 10
Abdominal pain 4 7
Constipation 3 17
Dizziness 3 8
Patients discontinuing therapy due to an adverse experience 9 24
Patients reporting at least 1 adverse experience 63 65

Although an equal percentage of patients receiving MEPRON and TMP-SMX reported at least 1 adverse experience, more patients receiving TMP-SMX required discontinuation of therapy due to an adverse event. Twenty-four percent of patients receiving TMP-SMX were prematurely discontinued from therapy due to an adverse experience versus 9% of patients receiving MEPRON. Four percent of patients receiving MEPRON had therapy discontinued due to development of rash. The majority of cases of rash among patients receiving MEPRON were mild and did not require the discontinuation of dosing. The only other clinical adverse experience that led to premature discontinuation of dosing of MEPRON by more than 1 patient was vomiting ( < 1%). The most common adverse experience requiring discontinuation of dosing in the TMP-SMX group was rash (8%).

Laboratory test abnormalities reported for ≥ 5% of the study population during the treatment period are summarized in Table 9. Two percent of patients treated with MEPRON and 7% of patients treated with TMP-SMX had therapy prematurely discontinued due to elevations in ALT/AST. In general, patients treated with MEPRON developed fewer abnormalities in measures of hepatocellular function (ALT, AST, alkaline phosphatase) or amylase values than patients treated with TMP-SMX.

Table 9: Treatment-Emergent Laboratory Test Abnormalities in the TMP-SMX Comparative PCP Treatment Study

Laboratory Test Abnormality Percentage of Patients Developing a Laboratory Test Abnormality
MEPRON TMP-SMX
Anemia (Hgb < 8.0 g/dL) 6 7
Neutropenia (ANC < 750 cells/mm³) 3 9
Elevated ALT ( > 5 x ULN) 6 16
Elevated AST ( > 5 x ULN) 4 14
Elevated alkaline phosphatase ( > 2.5 x ULN) 8 6
Elevated amylase ( > 1.5 x ULN) 7 12
Hyponatremia ( < 0.96 x LLN) 7 26
ULN = upper limit of normal range.
LLN = lower limit of normal range.

Table 10 summarizes the clinical adverse experiences reported by ≥ 5% of the primary therapy study population (n = 144) during the comparative trial of MEPRON and intravenous pentamidine, regardless of attribution. A slightly lower percentage of patients who received MEPRON reported occurrence of adverse events than did those who received pentamidine (63% vs 72%). However, only 7% of patients discontinued treatment with MEPRON due to adverse events, while 41% of patients who received pentamidine discontinued treatment for this reason (P < 0.001). Of the 5 patients who discontinued therapy with MEPRON, 3 reported rash (4%). Rash was not severe in any patient. No other reason for discontinuation of MEPRON was cited more than once. The most frequently cited reasons for discontinuation of pentamidine therapy were hypoglycemia (11%) and vomiting (9%).

Table 10: Treatment-Emergent Adverse Experiences in the Pentamidine Comparative PCP Treatment Study (Primary Therapy Group)

Treatment-Emergent Adverse Experience Percentage of Patients with Treatment-Emergent Adverse Experience
MEPRON
(n = 73)
Pentamidine
(n = 71)
Fever 40 25
Nausea 22 37
Rash 22 13
Diarrhea 21 31
Insomnia 19 14
Headache 18 28
Vomiting 14 17
Cough 14 1
Abdominal pain 10 11
Pain 10 10
Sweat 10 3
Monilia, oral 10 3
Asthenia 8 14
Dizziness 8 14
Anxiety 7 10
Anorexia 7 10
Sinusitis 7 6
Dyspepsia 5 10
Rhinitis 5 7
Taste perversion 3 13
Hypoglycemia 1 15
Hypotension 1 10
Patients discontinuing therapy due to an adverse experience 7 41
Patients reporting at least 1 adverse experience 63 72

Laboratory test abnormalities reported in ≥ 5% of patients in the pentamidine comparative study are presented in Table 11. Laboratory abnormality was reported as the reason for discontinuation of treatment in 2 of 73 patients who received MEPRON. One patient (1%) had elevated creatinine and BUN levels and 1 patient (1%) had elevated amylase levels. Laboratory abnormalities were the sole or contributing factor in 14 patients who prematurely discontinued pentamidine therapy. In the 71 patients who received pentamidine, laboratory parameters most frequently reported as reasons for discontinuation were hypoglycemia (11%), elevated creatinine levels (6%), and leukopenia (4%).

Table 11: Treatment-Emergent Laboratory Test Abnormalities in the Pentamidine Comparative PCP Treatment Study

Laboratory Test Abnormality Percentage of Patients Developing a Laboratory Test Abnormality
MEPRON Pentamidine
Anemia (Hgb < 8.0 g/dL) 4 9
Neutropenia (ANC < 750 cells/mm³) 5 9
Hyponatremia ( < 0.96 x LLN) 10 10
Hyperkalemia ( > 1.18 x ULN) 0 5
Alkaline phosphatase ( > 2.5 x ULN) 5 2
Hyperglycemia ( > 1.8 x ULN) 9 13
Elevated AST ( > 5 x ULN) 0 5
Elevated amylase ( > 1.5 x ULN) 8 4
Elevated creatinine ( > 1.5 x ULN) 0 7
ULN = upper limit of normal range.
LLN = lower limit of normal range.

Postmarketing Experience

In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of MEPRON. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to MEPRON.

Blood and Lymphatic System Disorders: Methemoglobinemia, thrombocytopenia.

Immune System Disorders:Hypersensitivity reactions including angioedema, bronchospasm, throat tightness, and urticaria.

Eye Disorders:Vortex keratopathy.

Gastrointestinal Disorders: Pancreatitis.

Hepatobiliary Disorders:Rare cases of hepatitis, and one case of fatal liver failure have been reported with atovaquone usage.

Skin and Subcutaneous Tissue Disorders: Erythema multiforme, Stevens-Johnson syndrome, and skin desquamation have been reported in patients receiving multiple drug therapy including atovaquone.

Renal and Urinary Disorders: Acute renal impairment.

Read the entire FDA prescribing information for Mepron (Atovaquone) »

A A A

Mepron - User Reviews

Mepron User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Mepron sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.